These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9199817)

  • 1. Evaluation of a new automated ELISA test for von Willebrand factor using two monoclonal antibodies.
    Pittet JL; Barbalat V; Sanvert M; Villard C; Jorieux S; Mazurier C
    Blood Coagul Fibrinolysis; 1997 Jun; 8(4):209-15. PubMed ID: 9199817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.
    Stufano F; Baronciani L; Mane-Padros D; Cozzi G; Faraudo S; Peyvandi F
    Haemophilia; 2018 Jan; 24(1):156-161. PubMed ID: 29168270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative evaluation of a new automated assay for von Willebrand factor activity.
    Lawrie AS; Stufano F; Canciani MT; Mackie IJ; Machin SJ; Peyvandi F
    Haemophilia; 2013 Mar; 19(2):338-42. PubMed ID: 23205618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an automated platelet-based assay of ristocetin cofactor activity.
    Lawrie AS; Mackie IJ; Machin SJ; Peyvandi F
    Haemophilia; 2011 Mar; 17(2):252-6. PubMed ID: 21070498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.
    Murdock PJ; Woodhams BJ; Matthews KB; Pasi KJ; Goodall AH
    Thromb Haemost; 1997 Oct; 78(4):1272-7. PubMed ID: 9364997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
    Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
    Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels.
    Federici AB; Canciani MT; Forza I; Mannucci PM; Marchese P; Ware J; Ruggeri ZM
    Haematologica; 2004 Jan; 89(1):77-85. PubMed ID: 14754609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA.
    Vanhoorelbeke K; Pareyn I; Schlammadinger A; Vauterin S; Hoylaerts MF; Arnout J; Deckmyn H
    Thromb Haemost; 2005 Jan; 93(1):165-71. PubMed ID: 15630508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.
    Favaloro EJ
    Am J Clin Pathol; 2000 Oct; 114(4):608-18. PubMed ID: 11026108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease.
    Zhao Y; Gu Y; Ji S; Yang J; Yu Z; Ruan C
    Eur J Haematol; 2012 May; 88(5):439-45. PubMed ID: 22268616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.
    Vanhoorelbeke K; Cauwenberghs N; Vauterin S; Schlammadinger A; Mazurier C; Deckmyn H
    Thromb Haemost; 2000 Jan; 83(1):107-13. PubMed ID: 10669163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor.
    Favaloro EJ; Grispo L; Dinale A; Berndt M; Koutts J
    Pathology; 1993 Apr; 25(2):152-8. PubMed ID: 8367196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms.
    Favaloro EJ; Facey D; Grispo L
    Am J Clin Pathol; 1995 Sep; 104(3):264-71. PubMed ID: 7677113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
    Favaloro EJ; Mohammed S
    Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems.
    Favaloro EJ; Henniker A; Facey D; Hertzberg M
    Thromb Haemost; 2000 Oct; 84(4):541-7. PubMed ID: 11057847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.